ABL Diagnostics signs LOI to buy Vela Diagnostics units in Singapore, US

By Public Technologies
  • ABL Texcell Diagnostics signed a non-binding letter of intent to buy Vela Diagnostics’ operations in Singapore and the US.
  • The deal targets 100% of Vela Operations Singapore and Vela Diagnostics USA from VDH Holding, parent of the Vela Group.
  • Transaction would extend coverage beyond EMEA into Asia-Pacific and the US, building on an existing EMEA distribution partnership.
  • Completion remains subject to due diligence and definitive documentation; no change in control is expected at ABL Texcell Diagnostics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260921418220) on September 21, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.